Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Oncotarget|November 19, 2016
A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemiaNeil E Kay, Paolo Strati, Betsy R LaPlant, et al.
Annals of Neurology|June 17, 2026
Gephyrin Neurological AutoimmunityMaria Chiara Pantuliano, Friederike A Arlt, Naomi Arenson, et al.
Blood|October 12, 2023
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trialDespoina Papazoglou, Xin Victoria Wang, Tait D Shanafelt, et al.
Annals of Neurology|April 18, 2024
Paraneoplastic Calmodulin Kinase-Like Vesicle-Associated Protein (CAMKV) Autoimmune EncephalitisMichael Gilligan, Connie E Lesnick, Yong Guo, et al.
Blood|August 15, 2022
Progression and survival of MBL: a screening study of 10 139 individualsSusan L Slager, Sameer A Parikh, Sara J Achenbach, et al.
Blood|April 20, 2021
The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLLSameer A Parikh, Kari G Rabe, Neil E Kay, et al.
Annals of Clinical and Translational Neurology|November 6, 2025
Insights Into the Antigenic Repertoire of Unclassified Synaptic AntibodiesMichael Gilligan, John R Mills, Paulina Vargas, et al.
Blood|August 18, 2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinibXin Victoria Wang, Curtis A Hanson, Renee C Tschumper, et al.
Leukemia|July 21, 2021
Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African AmericansGeffen Kleinstern, J Brice Weinberg, Sameer A Parikh, et al.
Pageof 1